Suvanza, Inc. (Suvanza) formerly CenterSpan Communications Corporation, is a producer and marketer of pharmaceutical products. The Company provides topical treatment with Mycophin anti-Fungal Gel. It has successfully completed clinical trials, for such indications as Onychomycosis, Tinea Capitis and Tinea Corporis. Suvanza’s delivery system uses less active ingredients, has reduced systemic uptake, and provides the opportunity to use multiple actives, which do not interact prior to application. The Company’s Technology consists of three components: Active Ingredient, Macro Bead Technology and Protecting Gel Vehicle. The Active Ingredient uses physical chemical modulation in nano vesicle formulation, for a targeted penetration in skin, hair and nails diseases. The Suvanza Technology targets disease sites such as skin surface, hair and nails, filling a void in topical therapy in those areas.